Price T Rowe Associates Inc. MD Reduces Position in DaVita Inc. (NYSE:DVA)

Price T Rowe Associates Inc. MD lowered its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 6.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 70,424 shares of the company's stock after selling 4,880 shares during the period. Price T Rowe Associates Inc. MD owned 0.09% of DaVita worth $10,533,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. United Capital Financial Advisors LLC grew its position in shares of DaVita by 2.6% during the 4th quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock valued at $361,000 after purchasing an additional 62 shares in the last quarter. Freedom Investment Management Inc. boosted its position in DaVita by 3.6% during the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock valued at $268,000 after buying an additional 62 shares during the period. Exchange Traded Concepts LLC grew its position in DaVita by 8.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock worth $133,000 after acquiring an additional 68 shares during the last quarter. Impact Partnership Wealth LLC increased its stake in shares of DaVita by 3.7% in the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock worth $290,000 after buying an additional 70 shares during the period. Finally, Contravisory Investment Management Inc. raised its stake in shares of DaVita by 1.2% during the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock valued at $910,000 after acquiring an additional 73 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analyst Ratings Changes

DVA has been the subject of several research reports. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Barclays lifted their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research report on Friday, February 21st. Finally, StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $166.33.

DaVita Stock Up 0.6 %

DaVita stock traded up $0.86 during mid-day trading on Wednesday, hitting $143.48. The company had a trading volume of 290,741 shares, compared to its average volume of 818,240. The stock's 50 day moving average price is $145.88 and its two-hundred day moving average price is $154.27. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The company has a market capitalization of $11.03 billion, a PE ratio of 13.35, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14. DaVita Inc. has a 12 month low of $131.44 and a 12 month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, sell-side analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.